- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 91,070 | 02.07.24 13:01:28 | -0,940 | -1,02% | 91,020 | 91,080 | 91,260 | 92,010 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 981,600 | 02.07.24 08:09:11 | +6,400 | +0,66% | 979,800 | 991,200 | 981,600 | 975,200 |
